BR112014029181B8 - Processo para identificar, diagnosticar ou fornecer um prognóstico - Google Patents

Processo para identificar, diagnosticar ou fornecer um prognóstico

Info

Publication number
BR112014029181B8
BR112014029181B8 BR112014029181A BR112014029181A BR112014029181B8 BR 112014029181 B8 BR112014029181 B8 BR 112014029181B8 BR 112014029181 A BR112014029181 A BR 112014029181A BR 112014029181 A BR112014029181 A BR 112014029181A BR 112014029181 B8 BR112014029181 B8 BR 112014029181B8
Authority
BR
Brazil
Prior art keywords
cells
rare cells
biological sample
rare
identify
Prior art date
Application number
BR112014029181A
Other languages
English (en)
Other versions
BR112014029181A2 (pt
BR112014029181B1 (pt
Inventor
Laget Sophie
Hofman Paul
Capiod Thierry
Paterlini-Brechot Patrizia
Original Assignee
Rarecells
Hopitaux Paris Assist Publique
Inst Nat Sante Rech Med
Patrizia Paterlini Brechot
Hofman Paul
Laget Sophie
Capiod Thierry
Univ Paris Descartes
Univ Paris
Univ Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rarecells, Hopitaux Paris Assist Publique, Inst Nat Sante Rech Med, Patrizia Paterlini Brechot, Hofman Paul, Laget Sophie, Capiod Thierry, Univ Paris Descartes, Univ Paris, Univ Paris Cite filed Critical Rarecells
Publication of BR112014029181A2 publication Critical patent/BR112014029181A2/pt
Publication of BR112014029181B1 publication Critical patent/BR112014029181B1/pt
Publication of BR112014029181B8 publication Critical patent/BR112014029181B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Abstract

PROCESSOS PARA IDENTIFICAR, DIAGNOSTICAR OU FORNECER UM PROGNÓSTICO, PARA DETECTAR A PRESENÇA OU AUSÊNCIA DE CÉLULAS RARAS, TRATAMENTO, COMPOSIÇÃO E KIT Processo para isolar ou extrair células raras a partir de uma amostra biológica que compreende filtrar uma amostra biológica, que pode ser tratada ou diluída, através de um filtro que tem um tamanho de poro, densidade de poro ou outras propriedades físicas que mantêm as células raras, mas que permitem que outros tipos de células passem através do filtro. Esse processo também compreende múltiplas análises realizadas em células raras, após a sua extração ou isolamento por filtração para identificar, por meio de diagnóstico, a presença de células raras em uma amostra biológica e usar sua identificação de diagnóstico e caracterização molecular para propósitos de diagnóstico, como para diagnóstico precoce de doenças, especialmente para diagnóstico precoce de câncer, e selecionar, orientar, monitorar tratamentos e, particularmente, selecionar tratamentos direcionados e monitorar a resposta e/ou resistência aos mesmos. Um kit que compreende ferramentas, equipamentos e/ou reagentes para realizar a etapa de filtração e vários tipos de análises múltiplas realizadas após isolamento e extração das células raras por filtração.
BR112014029181A 2012-05-24 2013-05-23 Processo para identificar, diagnosticar ou fornecer um prognóstico BR112014029181B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651437P 2012-05-24 2012-05-24
US61/651,437 2012-05-24
PCT/EP2013/060671 WO2013174948A1 (en) 2012-05-24 2013-05-23 Process for multi-analyses of rare cells extracted or isolated from biological samples through filtration

Publications (3)

Publication Number Publication Date
BR112014029181A2 BR112014029181A2 (pt) 2018-05-08
BR112014029181B1 BR112014029181B1 (pt) 2022-08-23
BR112014029181B8 true BR112014029181B8 (pt) 2022-11-22

Family

ID=48483085

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014029181A BR112014029181B8 (pt) 2012-05-24 2013-05-23 Processo para identificar, diagnosticar ou fornecer um prognóstico

Country Status (13)

Country Link
US (2) US20130316347A1 (pt)
EP (3) EP3745126A1 (pt)
JP (2) JP2015524054A (pt)
CN (2) CN104685356B (pt)
AU (2) AU2013265267C1 (pt)
BR (1) BR112014029181B8 (pt)
CA (2) CA2874048C (pt)
ES (1) ES2666594T3 (pt)
HK (1) HK1209186A1 (pt)
IL (1) IL235854A0 (pt)
MX (1) MX2014014245A (pt)
RU (2) RU2765808C2 (pt)
WO (1) WO2013174948A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2872344T3 (es) * 2014-07-02 2021-11-02 Siemens Healthcare Diagnostics Inc Separación selectiva de ácidos nucleicos
WO2016011414A1 (en) 2014-07-18 2016-01-21 Illumina, Inc. Non-invasive prenatal diagnosis of fetal genetic condition using cellular dna and cell free dna
CN104789468B (zh) * 2014-07-22 2017-10-20 奥克莱流体公司 颗粒筛选装置
US10564075B2 (en) 2015-02-24 2020-02-18 Siemens Healthcare Diagnostics Inc. Prefixation for increased rare cell recovery
KR101873318B1 (ko) 2015-09-30 2018-07-03 주식회사 싸이토젠 세포 이미징 장치 및 그 방법
JP6617516B2 (ja) * 2015-10-27 2019-12-11 東ソー株式会社 血液試料中に含まれる目的細胞の検出方法
CN105699641A (zh) * 2016-01-28 2016-06-22 山东省肿瘤防治研究院 一种外周血循环肿瘤细胞分离鉴定方法
CN105717104B (zh) * 2016-01-28 2018-05-29 山东省肿瘤防治研究院 一种肝细胞癌患者外周血gpc3检测方法
CA3049519A1 (en) * 2016-03-03 2017-09-08 Yasuiki UMEZU Method for detecting or separating/obtaining circulating tumor cell employing cell proliferation method
KR102064049B1 (ko) * 2016-07-25 2020-01-08 가부시끼가이샤 옵토니쿠스 세이미쯔 세포의 슬라이드 글래스 표본 제작 방법
GB201617713D0 (en) * 2016-10-19 2016-11-30 Q-Linea Ab Method for recovering microbial cells
CN106947735A (zh) * 2017-03-17 2017-07-14 内蒙古自治区农牧业科学院 一种简易分离卵母细胞或早期胚胎的方法
JP2018157812A (ja) * 2017-03-23 2018-10-11 東ソー株式会社 試料中に含まれる細胞の検出方法
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
KR101987065B1 (ko) * 2017-08-07 2019-06-10 주식회사 싸이토젠 Eml4-alk유전자 변이 분석방법
CN107653304A (zh) * 2017-10-11 2018-02-02 广州立菲达安诊断产品技术有限公司 一种用于检测kras基因突变的扩增引物、测序引物、试剂盒和方法
CN108009401B (zh) * 2017-11-29 2021-11-02 内蒙古大学 一种筛选指纹图谱遗传标记的方法
US10962454B2 (en) * 2018-07-28 2021-03-30 Leavitt Medical, Inc. Methods and systems for preparing cytological samples
US20210310008A1 (en) * 2018-08-07 2021-10-07 The Regents Of The University Of Colorado, A Body Corporate Parn as a biomarker and therapeutic target
JP7198452B2 (ja) * 2019-01-11 2023-01-04 公益財団法人がん研究会 末梢循環腫瘍細胞、及び希少細胞濃縮デバイス
CN111235272B (zh) * 2020-01-10 2023-07-07 厦门艾德生物医药科技股份有限公司 一次性检测肺癌多重基因突变的组合物及其应用
WO2021154965A1 (en) * 2020-01-31 2021-08-05 Luna Genetics, Inc. Determination of fetal genotype using maternal biological sample
RU2762317C1 (ru) * 2021-02-24 2021-12-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в основном опухолевом узле у больных раком молочной железы
CN112980779B (zh) 2021-05-20 2021-08-24 广州凯普医药科技有限公司 一种从孕妇宫颈脱落细胞中分离胎盘滋养层细胞的方法
CN113567672A (zh) * 2021-07-26 2021-10-29 江南大学附属医院 一种检测腹水或腹腔灌洗液中癌细胞的试剂盒
WO2023107839A1 (en) * 2021-12-06 2023-06-15 Cytobay Inc. Apparatuses and methods for cytopathological staining

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO931997A0 (en) * 1997-09-22 1997-10-09 Flinders Technologies Pty Ltd Enrichment and identification of trophoblast cells in maternal peripheral blood
EP1062515B1 (en) * 1998-02-12 2009-11-25 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
FR2824144B1 (fr) * 2001-04-30 2004-09-17 Metagenex S A R L Methode de diagnostic prenatal sur cellule foetale isolee du sang maternel
US7166443B2 (en) * 2001-10-11 2007-01-23 Aviva Biosciences Corporation Methods, compositions, and automated systems for separating rare cells from fluid samples
DE10238046A1 (de) * 2002-08-20 2004-03-04 Giesing, Michael, Prof. Dr.med. Verfahren zum Untersuchen von Körperflüssigkeiten auf Krebszellen, dessen Verwendung, entsprechende Analysekits und Verwendung bestimmter Wirkstoffe zur Behandlung von Krebs
US20050181429A1 (en) * 2003-04-03 2005-08-18 Monaliza Medical Ltd. Non-invasive prenatal genetic diagnosis using transcervical cells
JP5079506B2 (ja) * 2004-07-30 2012-11-21 プルリセレクト ゲーエムベーハー 動物についての、バイオテクノロジー（生物学的研究を含む）および医学的診断での適用のための、細胞、生体粒子および／または分子を液体から単離するための装置ならびに方法
FR2880897B1 (fr) * 2005-01-18 2010-12-17 Inst Nat Sante Rech Med Methode de detection, non invasive, prenatale, in vitro de l'etat sain normal, de l'etat de porteur sain ou de l'etat de porteur malade de la mucoviscidose
FR2883488B1 (fr) * 2005-03-24 2010-12-10 Inst Nat Sante Rech Med Procede et dispositif pour separer par filtration verticale des particules biologiques contenues dans un liquide
EP2589668A1 (en) * 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
CN101583722A (zh) * 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
US20080057505A1 (en) * 2006-07-14 2008-03-06 Ping Lin Methods and compositions for detecting rare cells from a biological sample
ITTO20070307A1 (it) * 2007-05-04 2008-11-05 Silicon Biosystems Spa Metodo e dispositivo per la diagnosi prenatale non-invasiva
FR2921490B1 (fr) * 2007-09-21 2010-09-10 Metagenex Procede et dispositif pour recueillir du materiel cellulaire de cellules isolees sur filtre
NZ601497A (en) * 2008-08-20 2014-03-28 Anthrogenesis Corp Improved cell composition and methods of making the same
RU2425385C1 (ru) * 2009-11-11 2011-07-27 Анатолий Агванович Чимитов Способ определения раковых клеток в периферической венозной крови у больных с подозрением на злокачественные новообразования
JP5704590B2 (ja) * 2010-02-05 2015-04-22 国立大学法人東京農工大学 サイズ選択マイクロキャビティアレイを用いた循環腫瘍細胞の検出
WO2011139445A1 (en) * 2010-05-03 2011-11-10 Creatv Microtech, Inc. Polymer microfilters and methods of manufacturing the same
WO2013072571A1 (fr) * 2011-11-17 2013-05-23 Institut Gustave Roussy Methode de caracterisation de cellules tumorales circulantes et application au diagnostic

Also Published As

Publication number Publication date
AU2018247219A1 (en) 2018-11-01
RU2765808C2 (ru) 2022-02-03
ES2666594T3 (es) 2018-05-07
CA2874048C (en) 2021-05-11
JP6761850B2 (ja) 2020-09-30
EP3351935B1 (en) 2020-08-12
EP2856153B1 (en) 2018-01-17
CN109517895A (zh) 2019-03-26
RU2017142155A3 (pt) 2021-01-28
HK1209186A1 (en) 2016-03-24
EP3351935A1 (en) 2018-07-25
CA2874048A1 (en) 2013-11-28
RU2017142155A (ru) 2019-02-13
EP3745126A1 (en) 2020-12-02
RU2014152244A (ru) 2016-07-20
BR112014029181A2 (pt) 2018-05-08
US20130316347A1 (en) 2013-11-28
AU2013265267A1 (en) 2014-12-18
AU2013265267C1 (en) 2019-01-31
CN104685356A (zh) 2015-06-03
WO2013174948A1 (en) 2013-11-28
AU2013265267B2 (en) 2018-08-02
US20200264166A1 (en) 2020-08-20
BR112014029181B1 (pt) 2022-08-23
JP2019074538A (ja) 2019-05-16
CN104685356B (zh) 2018-10-19
RU2641595C2 (ru) 2018-01-18
CN109517895B (zh) 2022-05-10
JP2015524054A (ja) 2015-08-20
CA3112123A1 (en) 2013-11-28
IL235854A0 (en) 2015-01-29
EP2856153A1 (en) 2015-04-08
MX2014014245A (es) 2015-06-17
AU2018247219B2 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
BR112014029181B8 (pt) Processo para identificar, diagnosticar ou fornecer um prognóstico
MX342735B (es) Diagnostico acompañante para terapia con agente anti-hialuronano y metodos de uso del mismo.
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2012011197A (es) Metodos, sistemas y dispositivos para separar celulas tumorales.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
WO2014028378A3 (en) Methods and systems for detecting biological components
WO2015102919A3 (en) Modular image analysis system and method
WO2011094535A3 (en) Biomarkers of aging for detection and treatment of disorders
WO2012051208A3 (en) Identifying rearrangements in a sequenced genome
EA201590027A1 (ru) Способы детекции заболеваний или состояний
WO2011087760A3 (en) Processes and kits for identifying aneuploidy
WO2015153732A3 (en) Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
WO2014065889A3 (en) Multiplexed method for diagnosing classical hodgkin lymphoma
MX2014004860A (es) Biomarcadores de cancer de pulmon y usos de los mismos.
WO2014152281A3 (en) Ribosomal ribonucleic acid hybridization for organism identification
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
AU2015308620A8 (en) Early lung cancer detection by DNA methylation phenotyping of sputum-derived cells
EP2977467A3 (en) Method, use of marker, and determination device for obtaining information on plural types of cancers
EA201691682A1 (ru) Способы анализирования редких циркулирующих в крови клеток
WO2015179777A3 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
GB201201766D0 (en) Method
AR090558A1 (es) Evento de maiz dp-004114-3 y metodos para su deteccion
ES2722900T3 (es) Portaobjetos para micromatrices y método para detectar algas tóxicas
WO2014153232A3 (en) Methods and compositions for diagnosing preeclampsia
WO2016051177A3 (en) Methods and kits

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 23/05/2013, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2694 DE 23/08/2022 QUANTO AO TITULO.

B25A Requested transfer of rights approved

Owner name: RARECELLS (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) ; PATRIZIA PATERLINI - BRECHOT (FR) ; PAUL HOFMAN (FR) ; SOPHIE LAGET (FR) ; THIERRY CAPIOD (FR) ; UNIVERSITE DE PARIS (FR)

B25D Requested change of name of applicant approved

Owner name: RARECELLS (FR) ; ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) ; PATRIZIA PATERLINI - BRECHOT (FR) ; PAUL HOFMAN (FR) ; SOPHIE LAGET (FR) ; THIERRY CAPIOD (FR) ; UNIVERSITE PARIS CITE (FR)